Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 4,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neck Neoplasms Clear all
Active, not recruiting Phase 2 Interventional

Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer

NCT05387915
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal HPV-Positive Squamous Cell Carcinoma
Interventions
Radiation Therapy
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 15, 2026, 1:33 AM EST
Active, not recruiting Phase 1 Interventional

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

NCT02474368
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer
Interventions
Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT)
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 1:33 AM EST
Terminated Phase 1 Interventional

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

NCT04624113
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Tazemetostat, Pembrolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Nov 15, 2026, 1:33 AM EST
Completed Not applicable Interventional

Enhanced Assistance During Radiotherapy for Unmet Essential Needs

NCT06582849
View directory record Official record
Conditions
Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Standard assistance, Enhanced assistance
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Nov 15, 2026, 1:33 AM EST
Terminated No phase listed Observational

Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer

NCT01949740
View directory record Official record
Conditions
Stage I Squamous Cell Carcinoma of the Oropharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Tongue Cancer
Interventions
questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 2 Interventional Results available

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

NCT00462735
View directory record Official record
Conditions
Head and Neck Cancer, Cancer of the Pharynx, Cancer of the Larynx, Nose Neoplasms, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
Interventions
Cetuximab, Hydroxyurea, Fluorouracil, radiotherapy
Drug · Procedure
Lead sponsor
Johnny Kao
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

NCT03692325
View directory record Official record
Conditions
Leukoplakia, Oral
Interventions
Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Nov 15, 2026, 1:33 AM EST
Recruiting No phase listed Observational

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

NCT03010150
View directory record Official record
Conditions
Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Carcinoma, Metastatic Malignant Neoplasm in the Uterine Cervix, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Nasopharyngeal Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 1:33 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Using CHWs and HPV Home Tests to Increase Cervical Cancer Screening in Minority Populations

NCT02121548
View directory record Official record
Conditions
Cervical Cancer
Interventions
CHW Outreach and HPV Self-sampling, CHW Outreach
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
601 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Nov 15, 2026, 1:33 AM EST
Recruiting Early Phase 1 Interventional

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

NCT05183048
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
[89Zr]Panitumumab Tracer
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 2 Interventional Results available

Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs)

NCT01405768
View directory record Official record
Conditions
Uterine Cervical Dysplasia
Interventions
sodium bicarbonate buffered lidocaine, Non-buffered lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 3 Interventional

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

NCT00000758
View directory record Official record
Conditions
HIV Infections, Cervix, Dysplasia
Interventions
Fluorouracil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 15, 2026, 1:33 AM EST
Completed No phase listed Observational Results available

Assess Vitamin D Levels in Those With & Without Thyroid Cancer

NCT00719615
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Nov 15, 2026, 1:33 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

NCT06611540
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028
View directory record Official record
Conditions
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Nov 15, 2026, 1:33 AM EST
Active, not recruiting Phase 2 Interventional

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

NCT06727565
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 15, 2026, 1:33 AM EST
Completed Not applicable Interventional

SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

NCT02986867
View directory record Official record
Conditions
Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
Interventions
SAbR Treatment of Lesions
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 2 Interventional Results available

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract

NCT00453336
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Interventions
Porfimer Sodium, Photodynamic Therapy
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 15, 2026, 1:33 AM EST
Recruiting Phase 2 Interventional

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

NCT06959511
View directory record Official record
Conditions
Neoadjuvant Treatment, Thyroid Cancer
Interventions
Zanzalintinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 1 Interventional Results available

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

NCT02783300
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3326595, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Denver, Colorado • Miami, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Nov 15, 2026, 1:33 AM EST
Completed Phase 1 Interventional

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

NCT00002949
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Endometrial Cancer, Vaginal Cancer
Interventions
paclitaxel, vinorelbine tartrate, radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Nov 15, 2026, 1:33 AM EST
Completed No phase listed Observational

Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer

NCT01084733
View directory record Official record
Conditions
Larynx Cancer, Lip Cancer, Oral Cavity Cancer, Pharyngeal Cancer, Oropharyngeal Cancer
Interventions
Not listed
Lead sponsor
Mahesh Kudrimoti
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Nov 15, 2026, 1:33 AM EST
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 15, 2026, 1:33 AM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700
View directory record Official record
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Nov 15, 2026, 1:33 AM EST